Welcome to our dedicated page for Research Alliance III SEC filings (Ticker: RACC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Research Alliance III's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Research Alliance III's regulatory disclosures and financial reporting.
Research Alliance Corp III (RACC), a Cayman Islands SPAC, plans to combine with OHB Pediatrics Ltd. (Oak Hill Bio), domesticate into Delaware and be renamed Oak Hill Bio Inc. The S-4 registers 9,098,529 shares of New OHB common stock for existing RACC shareholders, assuming no redemptions.
Immediately before closing, all Class B founder shares convert into Class A, redemptions of Class A public shares are effected, and each remaining Class A share becomes one New OHB share. Oak Hill Bio shareholders (including SAFE and option holders) will receive 16,000,000 New OHB shares based on a $160 million base equity value at $10.00 per share. A concurrent PIPE will raise $55 million via 5.5 million shares and/or pre-funded warrants at $10.00, and a backstop investor may buy up to 7.5 million shares (up to $75 million) to offset redemptions.
RACC’s trust held about $75.2 million on June 30, 2026, implying an estimated $10.03 per-share redemption value. Public holders can redeem (subject to a 15% cap per holder/group) while sponsors and insiders have waived redemptions and agreed to a six‑month lock-up. The proxy notes that public holders, who currently own about 82.4% of RACC, will experience immediate dilution and that sponsor economics and reimbursements create potential conflicts, though the board obtained a fairness opinion and unanimously recommends approval.
Research Alliance Corporation III received a Schedule 13G filing from ADAR1 Capital Management, LLC and its sole manager, Daniel Schneeberger, reporting a passive ownership stake in the company’s Class A Ordinary Shares. The reporting persons beneficially own 650,000 Class A Ordinary Shares through private investment funds managed by ADAR1 Capital Management, with shared voting and dispositive power over these shares and no sole voting or dispositive power. This position represents 8.4% of the 7,775,000 Class A Ordinary Shares outstanding as of June 30, 2026, based on the issuer’s Form 10-Q. ADAR1 Capital Management is reported as an investment adviser, and Schneeberger files as a control person with indirect beneficial ownership of the same shares.
Research Alliance Corporation III has a significant shareholder group led by TCG Crossover Fund III, L.P., TCG Crossover GP III, LLC, and Chen Yu reporting beneficial ownership of 500,000 Class A ordinary shares. This represents 6.4% of the Class A shares outstanding, based on 7,775,000 shares outstanding as of June 24, 2026.
The Reporting Persons have shared voting and dispositive power over 500,000 shares and no sole voting or dispositive power. The securities are held of record by TCG Crossover Fund III, L.P., with TCG Crossover GP III as general partner and Chen Yu as sole managing member. Each Reporting Person disclaims beneficial ownership beyond their pecuniary interest and expressly disclaims status as a group under the Exchange Act.
Balyasny Asset Management L.P. and related entities report a significant passive ownership position in Research Alliance Corporation III’s Class A common stock. Through Atlas Diversified Master Fund, Ltd., they are deemed to beneficially own 500,000 shares.
This position represents 6.43% of the Class A shares, based on 7,775,000 shares outstanding as of June 24, 2026. Each reporting person has sole voting and sole dispositive power over the 500,000 shares, with no shared voting or dispositive power. ADMF has the right to receive dividends and sale proceeds from these securities.
Spruce Street Capital LP, together with Alex R. Rosen and Simon Basseyn, reports beneficial ownership of Class A Ordinary Shares of Research Alliance Corp III. The group has shared voting and dispositive power over 500,000 Class A shares, representing 6.4% of the class.
The ownership percentage is based on 7,775,000 Class A Ordinary Shares outstanding as of June 24, 2026. Spruce Street Capital Master Fund LP has the right to receive dividends or sale proceeds from more than 5% of the outstanding Class A Ordinary Shares.
Research Alliance Corporation III, a Cayman Islands SPAC, reported June 30, 2026 results covering its first months since the May 21, 2026 IPO of 7,500,000 Class A shares at $10.00, raising $75,000,000. After investing proceeds, the Trust Account held $75,238,468 in U.S. Treasury securities, while cash outside the trust totaled $832,812 with working capital of $905,874.
The company recorded a net income of $54,050 for the quarter mainly from $238,468 of interest on trust investments; from inception to June 30, 2026 it recorded a small net loss. It has not begun operating activities and expects operating revenue only after completing a business combination.
On July 26, 2026, the company signed a Business Combination Agreement with OHB Pediatrics Ltd., plans to domesticate to Delaware and be renamed Oak Hill Bio, Inc., and secured a $45,000,000 SAFE financing for OHBP, a Backstop Agreement for up to 7,500,000 shares ($75,000,000), and a $55,000,000 PIPE in shares and pre-funded warrants, each subject to customary closing conditions and shareholder approvals. Management disclosed substantial doubt about the company’s ability to continue as a going concern based on current liquidity and timeline, and identified a material weakness in internal control over classification of accounts payable and accrued expenses, with remediation efforts underway.
Research Alliance Corporation III and OHB Pediatrics Ltd d/b/a Oak Hill Bio plan a SPAC business combination that would take Oak Hill Bio public on Nasdaq under the ticker OAKH, with the deal expected to close by the end of the year. The combined company is expected to launch with $175 million in cash, including $75 million from RACC’s trust account and a $100 million private financing, alongside Oak Hill’s recent $32.5 million Series A round.
Oak Hill Bio is developing rugonersen, an investigational antisense oligonucleotide for Angelman syndrome, licensed from Roche in 2025. Rugonersen is in the Phase 3 BEACON trial, with a primary completion date and an NDA submission planned for 2029. Angelman syndrome affects about 1 in 15,000 births, with around 500,000 patients worldwide, and competing Phase 3 programs from Ultragenyx and Ionis are underway. The communication emphasizes that rugonersen is investigational and includes extensive forward‑looking statement and risk disclosures about the transaction and development plans.
Bank of America Corporation, through its subsidiaries, reports beneficial ownership of 503,914 Class A Ordinary Shares of Research Alliance Corp III. This represents 6.5% of the class, based on 7,775,000 shares outstanding as reported by the issuer as of June 24, 2026.
All 503,914 shares are held with shared voting and shared dispositive power, with no sole voting or dispositive power. The position is held via wholly owned subsidiaries including BofA Securities, Inc. and Merrill Lynch International, and is reported on a passive ownership basis.
Research Alliance Corporation III is pursuing a proposed business combination with OHB Pediatrics Ltd. under a Business Combination Agreement dated July 26, 2026. The transaction will be submitted to RACC shareholders for approval.
RACC plans to file a registration statement on Form S-4 with the SEC, including a proxy statement/prospectus to solicit shareholder votes on the business combination and related matters. Shareholders and other investors are urged to read the registration statement, proxy statement/prospectus and related filings when available, as they will contain important information about RACC, OHB Pediatrics and the proposed transaction.
The communication contains extensive forward-looking statements about development timelines, regulatory approvals, financing, market opportunities and the timing and benefits of the combination, all subject to numerous risks and uncertainties, including regulatory approvals, redemptions by public shareholders, clinical and commercialization risks, and legal and market conditions. It also clarifies that the communication does not constitute an offer or solicitation to buy or sell securities, and that any securities offerings will be made only by a compliant prospectus.
Research Alliance Holdings III LLC and its manager Matthew Hammond report beneficial ownership of 1,520,269 Class A ordinary shares of Research Alliance Corporation III on an as-converted basis, representing 16.9% of 7,775,000 Class A shares outstanding as of June 24, 2026.
The amendment reflects a Business Combination Agreement under which Research Alliance Corporation III will acquire 100% of OHB Pediatrics Ltd. in exchange for newly issued common stock after a planned domestication from the Cayman Islands to Delaware and the one-for-one conversion of all Class B into Class A shares.
Consideration will equal an Adjusted Equity Value composed of a $160,000,000 base equity value plus the Company SAFE Amount, with shareholders offered cash redemptions equal to each share’s pro rata portion of the trust account. Additional terms include $45,000,000 of Company SAFEs at 8% interest, a backstop of up to 7,500,000 shares at $10.00 per share (up to $75,000,000), investor rights and lock-up agreements, and an expected closing in the second half of 2026 subject to regulatory, shareholder and other customary conditions.